Korean Market
MATR
NGeneBio
★★★

NGeneBio drastically lowers rights offering estimated price to 1,074 KRW, reducing proceeds to 7.68B KRW - deepening existing shareholder dilution

 
EXCH
NGeneBio
★★

NGeneBio Sets Ex-Rights Base Price at 1404 KRW for Rights Offering, Expected Dilution of About 18%

 
ISSU
NGeneBio
★★★★

NGeneBio Finalizes 80% Dilutive Rights Offering, Prospectus Effective; Financial Distress and Delisting Risk Intensify

 
ISSU
NGeneBio
★★★

NGeneBio 80% Rights Offering First Price Fixed at 1,074 KRW, Proceeds Slashed to 76.8 Billion KRW: Severe Dilution and Elevated Delisting Risk

 
EXCH
NGeneBio
★★★

NGeneBio Sets Rights Offering First Issue Price at 1,074 KRW, 37% Discount to Market Price, Raising Major Dilution Concerns

 
ETC
NGeneBio
★★★

NGeneBio Registration Statement for 80% Dilutive Rights Offering Becomes Effective, Materializing Equity Dilution and Financial Distress

 
ISSU
NGeneBio
★

NGeneBio Files Amendment to Securities Registration, Administrative Correction Only Without Finalizing Rights Offer Terms

 
MATR
NGeneBio
★

NGeneBio Amends Share Allocation Ratio for Rights Offering, Core Terms Unchanged

 
OWNR
NGeneBio
★

SH Healthcare Investment No.1 Association Plans OTC Sale of 785,559 Rights to Subscribe to NGeneBio Rights Offering to Secure Subscription Funds

 
OWNR
NGeneBio
★

SH Healthcare Investment No.1 Association Amends NGeneBio Shareholding Report by 1 Share Due to 3:1 Reverse Stock Split, Ownership Unchanged at 23%

 
OWNR
NGeneBio
★

SH Healthcare Investment No.1 Association Corrects 1-Share Discrepancy in NGeneBio Stake ... Purely Administrative Fix with No Financial Impact

 
EXCH
NGeneBio
★

NGeneBio Resumes Trading on July 13, 2026 After Capital Reduction and Change Listing

 
ISSU
NGeneBio
★★★

NGeneBio Finalizes 80% Dilutive Rights Offering Registration Statement – Severe Shareholder Dilution and Financial Risk

 
MATR
NGeneBio
★

NGeneBio Rights Offering Schedule Revision, All Dates Postponed Compared to Original Plan

 
EXCH
NGeneBio
★

NGeneBio Completes Massive 66.67% Capital Reduction, Share Consolidation Reshapes Shareholder Value